Centene Corp.

Centene Corp. has achieved a new 52-week high, reflecting a significant moment for the mid-cap healthcare services company with a market capitalization of USD 16,287 million. Despite this milestone, its one-year performance shows a decline, contrasting with broader market gains, and the company does not offer a dividend yield.

Centene Corp. has achieved a new 52-week high, reflecting a recovery from its previous low. Despite this, the company's one-year performance lags behind the S&P 500. With a market cap of approximately USD 16,287 million, Centene's financial metrics indicate a moderate valuation and a unique financial structure.

Centene Corp. has achieved a new 52-week high, reflecting a significant recovery from its previous low. Despite this milestone, the company's one-year performance lags behind the S&P 500. Centene's market capitalization stands at USD 16,287 million, with notable financial metrics indicating its unique market position.

Centene Corp. has achieved a new 52-week high of USD 62.09, marking a recovery despite a one-year performance decline of 11.23%. With a market cap of USD 17,692 million, the company has a P/E ratio of 27.00 and a price-to-book ratio of 0.89, indicating potential valuation insights.

Centene Corp. has seen a notable increase in its stock price, achieving significant gains over the past week and month. Despite recent positive performance, the company faces challenges with a decline over the past year and low financial metrics, including a modest return on equity. Its market capitalization stands at approximately USD 17.69 billion.

Centene Corp. experienced notable stock activity, achieving a significant intraday high amid a declining S&P 500. While the company has shown strong weekly and monthly gains, its longer-term performance reflects challenges, including a decline over the past year and three years, alongside financial metrics indicating operational difficulties.

Centene Corp., a midcap healthcare services company, has faced significant challenges over the past year, with a notable decline in stock performance compared to the S&P 500. Recent evaluations reflect the complexities of its market position, as technical indicators present a mixed outlook amid fluctuating stock prices.

Centene Corp., a midcap healthcare services company, has experienced a challenging year with a significant decline in stock performance compared to the S&P 500. Recent evaluations reflect mixed technical indicators, and the stock is currently trading within a defined range, highlighting ongoing market difficulties.

Centene Corp. faced notable volatility on March 10, 2026, with a significant stock price drop. Over the past week, the company has struggled, showing a substantial one-year loss compared to the S&P 500's gains. Financial metrics reveal low operating cash flow and a relatively low P/E ratio, indicating valuation concerns.

Centene Corp. faced a notable decline in its stock today, reflecting ongoing challenges in the healthcare services sector. Over the past year, the company has experienced significant losses, contrasting sharply with broader market gains. Its financial metrics indicate a conservative leverage approach, yet questions remain about its profitability efficiency.

Centene Corp. has seen notable stock activity, achieving a significant intraday high while outperforming the S&P 500 over the past week and month. Despite recent gains, the company has struggled over the past year, with a substantial decline compared to the broader market. Financial metrics indicate a strong balance sheet.

Centene Corp. has experienced significant stock activity, gaining 5.11% on October 3, 2025, with an intraday high of USD 38.85. Despite recent gains, the company faces long-term performance challenges, including a one-year decline of 46.28%. It maintains a P/E ratio of 8.00 and a return on equity of 7.71%.

Centene Corp. experienced a notable stock price increase on September 24, 2025, reaching an intraday high. However, the company has faced significant challenges over the past year, with a substantial decline in stock value. Its financial metrics indicate low valuation and no current dividends for shareholders.